CXCR4 Expression Predicts Patient Outcome and Recurrence Patterns after Hepatic Resection for Colorectal Liver Metastases
Authors:
- Adam C. YoppAYAdam C. Yopp
- Jinru ShiaJSJinru Shia
- Jean M. ButteJBJean M. Butte
- Peter J. AllenPAPeter J. Allen
- Yuman FongYFYuman Fong
- William R. JarnaginWJWilliam R. Jarnagin
- Ronald P. DeMatteoRDRonald P. DeMatteo
- 17 May 2011
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 19 (S3) , 339-346
Abstract
The purpose of this study was to determine if the expression of the chemokine receptors, CXCR4 and CCR7, and the chemokine ligand, CXCL12, in completely resected colorectal cancer hepatic metastases are predictive of disease-specific survival, recurrence-free survival and patterns of recurrence. Immunohistochemical analysis of CXCR4, CCR7 and CXCL12 expression within resected hepatic metastases was performed and correlated with clinicopathological variables, disease-specific survival, recurrence-free survival and patterns of recurrence. Seventy-five patients who underwent partial hepatectomy with curative intent were studied. CXCR4 expression (hazard ratio [HR] 3.6, 95% confidence interval [95% CI] 1.4-9.1) and clinical risk score >2 (HR 2.3, 95% CI 1.1-4.7) were independently associated with disease-specific survival by multivariate analysis. The 5-year estimated disease-specific survival rates for positive and negative CXCR4 tumor expression were 44 and 77%, respectively (P = 0.005). CXCR4 expression (HR 2.2, 95% CI 1.2-4.2) and clinical risk score >2 (HR 1.9, 95% CI 1.1-3.4) were independently associated with recurrence-free survival by multivariate analysis. The five year estimated recurrence-free survival rates for positive and negative CXCR4 tumor expression were 20 and 50%, respectively (P = 0.004). Neither CXCL12 nor CCR7 expression in tumors predicted disease-specific survival or recurrence-free survival. Forty-nine patients (65%) developed recurrent disease after initial hepatectomy. Negative CXCR4 tumor expression was associated with favorable recurrence patterns amenable to salvage resection and/or ablation. Negative CXCR4 expression in resected colorectal cancer hepatic metastases is independently associated with improved disease-specific and recurrence-free survival and favorable patterns of recurrence.Keywords
This publication has 39 references indexed in Scilit:
- Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasisClinical & Experimental Metastasis, 2009
- PI3Kγ activation by CXCL12 regulates tumor cell adhesion and invasionBiochemical and Biophysical Research Communications, 2009
- Hepatic stellate cells express functional CXCR4Hepatology, 2009
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid CancerCancer Research, 2007
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastasesClinical & Experimental Metastasis, 2007
- Chemokine Receptor CXCR4 Expression in Patients With Melanoma and Colorectal Cancer Liver Metastases and the Association With Disease OutcomeAnnals of Surgery, 2006
- Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experienceHPB, 2006
- CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironmentBlood, 2006
- In vivo and in vitro Interactions between Human Colon Carcinoma Cells and Hepatic Stellate CellsJapanese Journal of Cancer Research, 2000